Varma Mutual Pension Insurance Co Acquires Shares of 52,010 Stryker Corporation $SYK

Varma Mutual Pension Insurance Co purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 52,010 shares of the medical technology company’s stock, valued at approximately $16,375,000.

Other large investors also recently added to or reduced their stakes in the company. QRG Capital Management Inc. raised its stake in Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB increased its holdings in Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after buying an additional 7,934 shares during the period. Crossmark Global Holdings Inc. raised its position in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Royal Bank of Canada grew its position in shares of Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after acquiring an additional 199,863 shares during the period. Finally, Rathbones Group PLC increased its position in shares of Stryker by 647.9% in the fourth quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock valued at $77,065,000 after buying an additional 189,948 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent research reports. BTIG Research cut their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Truist Financial upped their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Price Performance

SYK stock opened at $329.86 on Friday. The company has a market capitalization of $126.52 billion, a PE ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76. The stock’s 50 day moving average is $326.99 and its two-hundred day moving average is $332.64. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the firm earned $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Buying and Selling

In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 665,370 shares of company stock valued at $216,238,501. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.